Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults

被引：53

作者：

Gorse, Geoffrey J. ^{[1
,2
]}

Baden, Lindsey R. ^{[3
]}

Wecker, Margaret ^{[4
]}

Newman, Mark J. ^{[5
]}

Ferrari, Guido ^{[6
]}

Weinhold, Kent J. ^{[6
]}

Livingston, Brian D. ^{[5
]}

Villafana, Tonya L. ^{[7
]}

Li, Hongli ^{[8
]}

Noonan, Elizabeth ^{[8
]}

Russell, Nina D. ^{[4
]}

机构：

[1] St Louis Univ, Sch Med, Div Infect Dis & Immunol, St Louis, MO 63104 USA

[2] Dept Vet Affairs Med Ctr, St Louis, MO USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] HVTN, Seattle, WA USA

[5] Pharmexa Epimmune Inc, San Diego, CA USA

[6] Duke Univ, Durham, NC USA

[7] Botswana Harvard Sch Publ Hlth AIDS Intiat, Gaborone, Botswana

[8] Fred Hutchinson Canc Res Ctr, SCHARP, Seattle, WA 98104 USA

[9] Core Operat Ctr, HVTN, Seattle, WA USA

来源：

VACCINE | 2008年 / 26卷 / 02期

关键词：

HIV-1; vaccines; cytotoxic T-lymphocyte; DNA plasmid; epitopes; HLA supertypes; interferon-gamma; Botswana;

D O I：

10.1016/j.vaccine.2007.10.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebocontrolled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0 mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：215 / 223

页数：9

共 61 条

[1]

Alexander J, 1997, J IMMUNOL, V159, P4753

[2]

DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].

ALEXANDER, J ;

SIDNEY, J ;

SOUTHWOOD, S ;

RUPPERT, J ;

OSEROFF, C ;

MAEWAL, A ;

SNOKE, K ;

SERRA, HM ;

KUBO, RT ;

SETTE, A ;

GREY, HM .

IMMUNITY, 1994, 1 (09) :751-761

[3]

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen [J].

Allen, TM ;

Vogel, TU ;

Fuller, DH ;

Mothé, BR ;

Steffen, S ;

Boyson, JE ;

Shipley, T ;

Fuller, J ;

Hanke, T ;

Sette, A ;

Altman, JD ;

Moss, B ;

McMichael, AJ ;

Watkins, DI .

JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4968-4978

[4]

Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif [J].

Altfeld, MA ;

Livingston, B ;

Reshamwala, N ;

Nguyen, PT ;

Addo, MM ;

Shea, A ;

Newman, M ;

Fikes, J ;

Sidney, J ;

Wentworth, P ;

Chesnut, R ;

Eldridge, RL ;

Rosenberg, ES ;

Robbins, GK ;

Brander, C ;

Sax, PE ;

Boswell, S ;

Flynn, T ;

Buchbinder, S ;

Goulder, PJR ;

Walker, BD ;

Sette, A ;

Kalams, SA .

JOURNAL OF VIROLOGY, 2001, 75 (03) :1301-1311

[5]

A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease [J].

Amara, RR ;

Patel, K ;

Niedziela, G ;

Nigam, P ;

Sharma, S ;

Staprans, SI ;

Montefiori, DC ;

Chenareddi, L ;

Herndon, JG ;

Robinson, HL ;

McClure, HM ;

Novembre, FJ .

JOURNAL OF VIROLOGY, 2005, 79 (24) :15356-15367

[6]

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine [J].

Amara, RR ;

Smith, JM ;

Staprans, SI ;

Montefiori, DC ;

Villinger, F ;

Altman, JD ;

O'Neil, SP ;

Kozyr, NL ;

Xu, Y ;

Wyatt, LS ;

Earl, PL ;

Herndon, JG ;

McNicholl, JM ;

McClure, HM ;

Moss, B ;

Robinson, HL .

JOURNAL OF VIROLOGY, 2002, 76 (12) :6138-6146

[7]

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[8]

[Anonymous], 1993, Resampling-based multiple testing: Examples and methods for P-value adjustment

[9]

Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines [J].

Anwer, K ;

Earle, KA ;

Shi, M ;

Wang, JJ ;

Mumper, RJ ;

Proctor, B ;

Jansa, K ;

Ledebur, HC ;

Davis, S ;

Eaglstein, W ;

Rolland, AP ;

Rolland, P .

PHARMACEUTICAL RESEARCH, 1999, 16 (06) :889-895

[10]

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].

Barouch, DH ;

Santra, S ;

Schmitz, JE ;

Kuroda, MJ ;

Fu, TM ;

Wagner, W ;

Bilska, M ;

Craiu, A ;

Zheng, XX ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Nickerson, CE ;

Trigona, WL ;

Punt, K ;

Freed, DC ;

Guan, LM ;

Dubey, S ;

Casimiro, D ;

Simon, A ;

Davies, ME ;

Chastain, M ;

Strom, TB ;

Gelman, RS ;

Montefiori, DC ;

Lewis, MG ;

Emini, EA ;

Shiver, JW ;

Letvin, NL .

SCIENCE, 2000, 290 (5491) :486-492

← 1 2 3 4 5 6 7 →